LONDON (Reuters) - The healthcare cost-effectiveness watchdog said on Wednesday that Eli Lilly and Co's drug Alimta would not be recommended as a treatment for lung cancer on the state health service. The National Institute for Health and Clinical Excellence (NICE) said its experts had rejected an appeal against the decision by Lilly, because they were not convinced of the clinical and cost effectiveness of Alimta compared with other lung cancer treatments.
